IGNE.US Igene Biotechnology Inc
- Market cap
- USD 15.7K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2010.
Is IGNE.US undervalued?
Graham numberThe Graham number of Igene Biotechnology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Igene Biotechnology Inc fundamental analysis
No fundamental analysis for Igene Biotechnology Inc yet.
Igene Biotechnology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Igene Biotechnology Inc
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry. The company also provides research and development services for microbial strain improvement and fermentat…
Full company profileIgene Biotechnology Inc financial statements
2010 annualized: Fiscal year 2010 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2010, the balance sheet is the latest quarter. Figures change when the annual report is published.
Igene Biotechnology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 703K | 4.18M | 3.49M | 463K | - | - | 0.00 | 2.29M | 7.64M | 3.96M | 0.00 |
| Gross Profit | 11.4K | 664K | 324K | 17.3K | - | - | 0.00 | 605K | 1.25M | 1.02M | 0.00 |
| Operating Income | -1.51M | -1.64M | -1.85M | -625K | - | - | -417K | 238K | -2.19M | -1.07M | -2.65M |
| EBITDA | -1.41M | -1.50M | -1.67M | -541K | - | - | -308K | 325K | -2.08M | -851K | -342K |
| Net Income | -2.26M | -3.67M | -3.19M | -2.20M | - | - | -1.16M | -1.90M | -3.99M | -141K | -2.65M |
| EPS | -0.04 | -0.05 | -0.04 | -0.02 | - | - | -0.01 | -0.02 | -0.02 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 2.01M | 3.54M | 3.21M | 12.4M | 496K | 231K | 74.6K | 13.1M | 6.07M | 4.76M | 3.41M |
| Total Liabilities | 9.82M | 14.5M | 17.0M | 16.3M | 14.6M | 15.4M | 16.5M | 27.5M | 8.74M | 7.50M | 8.10M |
| Shareholders' Equity | -7.81M | -11.0M | -13.8M | -3.92M | -14.1M | -15.1M | -16.4M | -14.4M | -2.68M | -2.74M | -4.69M |
| Cash & Short-term Investments | 144K | 394K | 498K | 63.1K | 204K | 120K | 21.8K | 1.03M | 1.49M | 1.30M | 269K |
| Total Debt | 8.18M | 11.1M | 11.1M | 10.7M | - | - | 16.0M | 19.3M | 5.35M | 6.80M | 7.34M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.81M | -2.14M | -1.31M | -174K | 303K | 290K | 100.00 | 1.31M | 706K | -97.0K | -1.35M |
| Capital Expenditure | 8.98K | 69.5K | 100K | 0.00 | 0.00 | 0.00 | 275K | 275K | 226K | 172K | 20.8K |
| Free Cash Flow | -1.82M | -2.21M | -1.41M | -174K | - | - | 100.00 | 1.04M | 479K | -269K | -1.36M |
| Ratios | |||||||||||
| ROA | -112.0% | -103.8% | -99.4% | -17.7% | - | - | -1,549.8% | -14.5% | -65.8% | -3.0% | -77.6% |
| Net Profit Margin | -321.0% | -87.8% | -91.4% | -474.5% | - | - | - | -83.0% | -52.2% | -3.6% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Igene Biotechnology Inc dividends
Igene Biotechnology Inc has not paid dividends in the last 9 fiscal years.
Who owns Igene Biotechnology Inc
- Insiders 0.00%
- Institutions 0.47%
- Public & others 99.53%
- Shares outstanding 1.57B
Igene Biotechnology Inc company profile
- Company name
- Igene Biotechnology Inc
- Ticker
- IGNE.US
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 18
- Fiscal year end
- December
- Address
- 9110 Red Branch Road, Columbia, MD, United States, 21045
- Phone
- 410-997-2599
- Website
- igene.com
About Igene Biotechnology Inc
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry. The company also provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors; and analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. The company was formerly known as IGI Biotechnology, Inc. and changed its name to IGENE Biotechnology, Inc. in April 1986. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland.
Igene Biotechnology Inc management
1- Mr. Joseph L. DownsChief Executive Officer